临床定义痛风及其亚型的全基因组关联研究识别出包括尿酸转运体基因在内的多个易感位点
该研究对945例日本男性临床定义痛风患者和1213例对照进行GWAS,并在1396例病例和1268例对照中验证,还首次对痛风亚型进行GWAS。除已知5个位点外,新发现SLC22A12、SLC17A1和HIST1H2BF-HIST1H4E与全部痛风相关,NIPAL1和FAM35A与肾脏尿酸排泄减少亚型相关;FAM35A在三个人群meta分析中达全基因组显著性。
要点
- 新发现SLC22A12、SLC17A1和HIST1H2BF-HIST1H4E与全部痛风在全基因组水平显著相关。
- NIPAL1和FAM35A与肾脏尿酸排泄减少痛风亚型相关,NIPAL1功能分析未检测到尿酸转运。
- FAM35A在三个人群meta分析中与全部痛风达全基因组显著性(p meta=3.58×10-8)。
核心结论
- 除既往报道的5个位点外,研究识别出多个新的痛风易感位点,增进了对痛风分子发病机制的理解,并为痛风/高尿酸血症治疗靶点提供新概念。
研究设计与样本
- 对945例日本男性临床定义痛风病例和1213例对照进行GWAS,并用1961个SNP定制芯片在1396例病例和1268例对照中验证。
- 首次对痛风亚型进行GWAS,并在高加索和新西兰波利尼西亚样本中进行重复验证。
主要发现
- 在全基因组显著性水平(p<5.0×10-8)下,SLC22A12、SLC17A1和HIST1H2BF-HIST1H4E与全部痛风病例相关。
- NIPAL1和FAM35A与肾脏尿酸排泄减少痛风亚型相关;NIPAL1编码镁转运体,功能分析未检测到其转运尿酸。
- 人肾脏定位分析显示NIPAL1和FAM35A主要表达于远端小管,提示远端肾单位参与人类尿酸处理。
- 高加索和波利尼西亚裔男性痛风患者及对照的基因分型显示FAM35A与全部痛风病例相关。
- 三个人群meta分析显示FAM35A与痛风在全基因组显著性水平相关(p meta=3.58×10-8)。
关键数值与推荐
- 全基因组显著性阈值定义为p<5.0×10-8。
- FAM35A与痛风在三人群meta分析中关联的p meta=3.58×10-8。
临床怎么用
- 新识别的位点(如SLC22A12、SLC17A1、FAM35A等)有助于理解痛风遗传易感性,并可能为痛风/高尿酸血症治疗靶点提供新方向。
局限性
- NIPAL1功能分析未检测到尿酸转运活性,其与尿酸处理的关联可能为间接作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: A genome-wide association study (GWAS) of gout and its subtypes was performed to identify novel gout loci, including those that are subtype-specific. METHODS: Putative causal association signals from a GWAS of 945 clinically defined gout cases and 1213 controls from Japanese males were replicated with 1396 cases and 1268 controls using a custom chip of 1961 single nucleotide polymorphisms (SNPs). We also first conducted GWASs of gout subtypes. Replication with Caucasian and New Zealand Polynesian samples was done to further validate the loci identified in this study. RESULTS: In addition to the five loci we reported previously, further susceptibility loci were identified at a genome-wide significance level (p<5.0×10-8): urate transporter genes (SLC22A12 and SLC17A1) and HIST1H2BF-HIST1H4E for all gout cases, and NIPAL1 and FAM35A for the renal underexcretion gout subtype. While NIPAL1 encodes a magnesium transporter, functional analysis did not detect urate transport via NIPAL1, suggesting an indirect association with urate handling. Localisation analysis in the human kidney revealed expression of NIPAL1 and FAM35A mainly in the distal tubules, which suggests the involvement of the distal nephron in urate handling in humans. Clinically ascertained male patients with gout and controls of Caucasian and Polynesian ancestries were also genotyped, and FAM35A was associated with gout in all cases. A meta-analysis of the three populations revealed FAM35A to be associated with gout at a genome-wide level of significance (p meta =3.58×10-8). CONCLUSIONS: Our findings including novel gout risk loci provide further understanding of the molecular pathogenesis of gout and lead to a novel concept for the therapeutic target of gout/hyperuricaemia.
引用
- Nakayama A, Nakaoka H, Yamamoto K, et al. GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genes. Ann Rheum Dis. 2016. PMID: 27899376. doi:10.1136/annrheumdis-2016-209632
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。